Notice of Public Hearing
Pursuant to subsection D of § 54.1-3443, the Board of Pharmacy is giving notice of a public hearing to consider placement of chemical substances in Schedule I of the Drug Control Act. The public hearing will be conducted at 9:00 a.m. on December 9, 2014 at the Perimeter Center, 9960 Mayland Drive, Suite 201, Board Room 2, Richmond, VA 23233. Public comment may also be submitted prior to December 9, 2014 to Caroline Juran, Executive Director of the Board of Pharmacy to firstname.lastname@example.org.
As specified in § 54.1-3443, the Virginia Department of Forensic Science (DFS) has identified three (3) compounds for recommended inclusion by the Board of Pharmacy into Schedule I in the Code of Virginia. We believe the Drug Enforcement Administration (DEA) is currently working to place these compounds into Schedule I Federally. Other drugs of this type have been placed in Schedule I in previous legislative sessions. A brief description and chemical name for each compound is as follows:
1. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (other name: AB-CHMINACA) AB-CHMINACA is classified as a cannabimimetic agent and has been identified in all four (4) DFS laboratories.
2. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide(other name: 5-fluoro-AMB) 5-fluoro-AMB is classified as a cannabimimetic agent and has been identified in two (2) of the four (4) DFS laboratories.
3. 3,4-methylenedioxy-N,N-dimethylcathinone (other names: Dimethylone, bk-MDDMA) Dimethylone is classified as a substituted cathinone, and has been identified in two (2) of the four (4) DFS laboratories.
If approved by the Board of Pharmacy, the placement of these substances in Schedule I in the Virginia Drug Control Act shall remain in effect for a period of 18 months from the date of Board action and shall then be de-scheduled unless the Drug Control Act is amended by enactment of legislation by the General Assembly.